AUTHOR=Yang Lei , Yang Zelin , Zuo Chunjian , Lv Xiaolong , Liu Tianyu , Jia Chenhao , Chen Huanwen 

TITLE=Epidemiological evidence for associations between variants in CHRNA genes and risk of lung cancer and chronic obstructive pulmonary disease

JOURNAL=Frontiers in Oncology

VOLUME=12

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.1001864

DOI=10.3389/fonc.2022.1001864

ISSN=2234-943X

ABSTRACT=<sec><title>Background</title><p>Genetic studies have previously reported that single-nucleotide polymorphisms (SNPs) in <italic>CHRNA</italic> genes (such as <italic>CHRNA3</italic>, <italic>CHRNA4</italic>, <italic>CHRNA5</italic>, or <italic>CHRNA3-CHRNA5-CHRNB4</italic> clusters) are linked to the risk of neoplastic and non-neoplastic diseases. However, these conclusions were controversial and no systematic research synopsis has been available. We aimed to synthesize current knowledge of variants in the <italic>CHRNA</italic> genes on the risk of diseases.</p></sec><sec><title>Methods</title><p>We systematically searched for publications using PubMed, Medline, and Web of Science on or before 25 August 2021. A total of 1,818 publications were identified, of which 29 were deemed eligible for inclusion that could be used to perform meta-analysis based on at least three data sources to assess whether the morbidity associated with neoplastic and non-neoplastic diseases can be attributed to SNPs in <italic>CHRNA</italic> genes. To further evaluate the authenticity of cumulative evidence proving significant associations, the present study covered the Venice criteria and false-positive report probability tests. Through the Encyclopedia of DNA Elements (ENCODE) project, we created functional annotations for strong associations.</p></sec><sec><title>Results</title><p>Meta-analyses were done for nine genetic variants with two diseases {chronic obstructive pulmonary disease (COPD) and lung cancer (LC)}that had at least three data sources. Interestingly, eight polymorphisms were significantly related to changes in the susceptibility COPD and LC (<italic>p</italic> &lt; 0.05). Of these, strong evidence was assigned to six variants (28 significant associations): <italic>CHRNA3</italic> rs1051730, <italic>CHRNA3</italic> rs6495309, and <italic>CHRNA5</italic> rs16969968 with COPD risk, and <italic>CHRNA3</italic> rs1051730, <italic>CHRNA3</italic> rs578776, <italic>CHRNA3</italic> rs6495309, <italic>CHRNA3</italic> rs938682, <italic>CHRNA5</italic> rs16969968, and <italic>CHRNA5</italic> rs588765 with LC risk; moderate evidence was assigned to five SNPs (12 total associations) with LC or COPD risk. Data from ENCODE and other public databases showed that SNPs with strong evidence may be located in presumptive functional regions.</p></sec><sec><title>Conclusions</title><p>Our study summarized comprehensive evidence showing that common mutations in <italic>CHRNA</italic> genes are strongly related to LC and COPD risk. The study also elucidated the vital function of <italic>CHRNA</italic> genes in genetic predispositions to human diseases.</p></sec>